Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Izuforant in Moderate to Severe Atopic Dermatitis
NCT05117060Phase 2Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Dec 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of JW1601 in atopic dermatitis (AD) (4 arms), sponsored by JW Pharmaceutical Corporation. Primary endpoint: Change in Eczema Area and Severity Index From Baseline at Week 16. Started Dec 2021; status: completed.
02
Drugs
JW1601
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05117060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05117060.